Tvardi Therapeutics, Inc. (TVRD)

Market Cap	245.21M
Revenue (ttm)	n/a
Net Income (ttm)	-34.77M
Shares Out	9.36M
EPS (ttm)	-5.43
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	31,875
Open	25.72
Previous Close	25.69
Day's Range	25.72 - 25.96
52-Week Range	8.13 - 34.31
Beta	n/a
Analysts	Strong Buy
Price Target	59.20 (+125.87%)
Earnings Date	Aug 21, 2025

About ANSS

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 2 clinical development for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in pre-clinical stage....

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 12
• Stock Exchange: NASDAQ
• Ticker Symbol: TVRD
• Website: https://tvarditherapeutics.com

Analyst Summary

According to 5 analysts, the average rating for TVRD stock is "Strong Buy." The 12-month stock price target is $59.2, which is an increase of 125.87% from the latest price.

Price Target

$59.2

(125.87% upside)

Analyst Consensus: Strong Buy